Protein Intake During Major Weight Loss
APhase 3 EvidenceAdequate dietary protein is the single most evidence-supported nutritional strategy during significant pharmacological weight loss. GLP-1 receptor agonists suppress appetite broadly — protein intake must be intentional.
- General recommendation: 1.2–1.6 g protein per kg of body weight per day during active weight loss
- Higher protein intakes (up to 2.0 g/kg) may be warranted with concurrent resistance training
- Protein has the highest thermic effect of food (~25–30% of calories burned in digestion)
- Protein is the most satiating macronutrient per calorie — important when appetite is suppressed
- Leucine-rich sources (animal protein, whey, soy) are most effective for muscle protein synthesis
- Distributing protein across 3–4 meals maximizes muscle protein synthesis vs. one large serving
Evidence note: Protein recommendations are based on general weight loss literature. Retatrutide-specific protein intake data has not been published.
Preserving Lean Mass During Rapid Weight Loss
BPhase 1/2 EvidenceRapid weight loss from any cause — including GLP-1 therapy — can result in loss of lean mass alongside fat. The proportion of lean vs. fat mass lost depends on protein intake, exercise, and rate of weight loss.
- Phase 2 retatrutide data showed substantial total weight loss; lean mass composition was not the primary endpoint
- Resistance training is the most effective intervention for preserving lean mass during caloric restriction
- Even 2–3 sessions per week of progressive resistance training significantly reduces lean mass loss
- Adequate protein intake (see above) is synergistic with resistance training for lean mass preservation
- Very rapid weight loss (>1% body weight/week) is associated with greater lean mass loss
- Creatine supplementation has modest evidence for supporting lean mass during weight loss
Evidence note: Lean mass preservation data specific to retatrutide is not yet published. Recommendations are extrapolated from GLP-1 class and general weight loss literature.
Managing GI Side Effects Through Diet
BPhase 1/2 EvidenceNausea, vomiting, and other GI symptoms are the most common adverse effects of GLP-1 receptor agonists. Dietary strategies can meaningfully reduce symptom severity, particularly during dose escalation.
- Eat smaller, more frequent meals rather than large meals — gastric emptying is slowed by GLP-1 agonism
- Avoid high-fat, fried, or greasy foods during dose escalation — these worsen nausea
- Avoid lying down immediately after eating — elevate the head of the bed if nighttime reflux occurs
- Ginger (tea, capsules, or candied) has modest evidence for reducing nausea
- Stay well hydrated — vomiting and reduced food intake can cause dehydration
- Bland, low-fat foods (crackers, toast, rice, bananas) are better tolerated during peak nausea
- Symptoms typically improve after 4–8 weeks at a stable dose
Evidence note: GI management strategies are based on GLP-1 class data and general gastroenterology guidance, not retatrutide-specific studies.
Micronutrient Considerations During Caloric Restriction
BPhase 1/2 EvidenceSignificant caloric restriction reduces total micronutrient intake. Deficiencies in key vitamins and minerals are common during major weight loss and should be proactively addressed.
- A comprehensive multivitamin is generally recommended during major weight loss
- Vitamin D and calcium are commonly deficient — particularly important for bone health during weight loss
- Iron deficiency is more common in women and in those with reduced red meat intake
- B12 deficiency risk increases with reduced animal protein intake
- Magnesium is frequently inadequate in Western diets and may worsen with reduced food intake
- Electrolyte imbalances (sodium, potassium) can occur with vomiting or very low calorie intake
- Zinc supports immune function and wound healing — often reduced during caloric restriction
Evidence note: Micronutrient recommendations are based on general weight loss and bariatric surgery literature. Individual needs vary — consult a registered dietitian.
Hydration During GLP-1 Therapy
CIndirect Human EvidenceAdequate hydration is particularly important during GLP-1 therapy due to reduced food intake (foods contribute ~20% of daily water intake), potential GI fluid losses, and the risk of dehydration-related adverse effects.
- Aim for at least 2–2.5 liters of fluid per day from all sources
- Water, herbal teas, and electrolyte drinks are preferable to sugary beverages
- Alcohol should be used cautiously — it is calorie-dense, dehydrating, and may worsen GI symptoms
- Signs of dehydration: dark urine, dizziness, headache, fatigue — seek medical attention if severe
- Carbonated beverages may worsen nausea and bloating in some individuals
- Coffee and caffeinated beverages count toward fluid intake but may worsen GI symptoms in some
Evidence note: Hydration recommendations are general guidance. No retatrutide-specific hydration data has been published.
Meal Timing and Eating Patterns
CIndirect Human EvidenceGLP-1 receptor agonists significantly alter hunger and satiety signals. Structured eating patterns may help maintain adequate nutrition when appetite is substantially suppressed.
- Scheduled meals (rather than eating only when hungry) help ensure adequate intake when appetite is suppressed
- Skipping meals due to lack of appetite can lead to inadequate protein and micronutrient intake
- Time-restricted eating (intermittent fasting) may be difficult to combine with GLP-1 therapy — consult a physician
- Eating slowly and mindfully is particularly important with slowed gastric emptying
- Avoid eating within 2–3 hours of bedtime to reduce reflux risk
- Protein-first eating (consuming protein before carbohydrates at each meal) may improve satiety and protein targets
Evidence note: Meal timing recommendations are based on general nutrition science and GLP-1 class guidance, not retatrutide-specific data.